The next generation of drugs targeting a key pathway in neurodegeneration.
KEAPSTONE THERAPEUTICS is developing a novel series of small molecule activators of the Nrf2-ARE pathway for neuroprotection in Parkinson’s and amyotrophic lateral sclerosis (ALS).
We are developing CNS penetrant, non-reactive small molecules that prevent KEAP1 from interacting with Nrf2
By blocking this interaction, we can drive Nrf2 into the nucleus to activate a range of cellular defence pathways that improve redox balance and mitochondrial function, promote autophagy and limit inflammation. Uniquely, this approach allows multiple pathways to be targeted by a single drug.
